Core Points - KALA BIO Inc. experienced a significant stock price increase of 37.87% to $0.88 in after-hours trading, following a regular session close at $0.64, which was a 3.45% increase [1][6] Financing and Agreements - KALA BIO entered into a Securities Purchase Agreement with investor David Lazar to raise up to $6 million through a private placement, as disclosed in an SEC Form 8-K filing [2] - The first closing raised $1.8 million from the sale of 900,000 Series AA Preferred Shares at $2 each, while a second closing is expected to raise $4.2 million through 2.1 million Series AAA Preferred Shares at $2 each, pending stockholder approval [3] Loan Settlement - KALA BIO reached a loan settlement agreement with Oxford Finance LLC, which requires a $2 million cash payment and the issuance of 1.62 million common stock shares [4] - Upon completion of an initial $1 million payment by January 15, 2026, or the stockholder meeting date, and stock issuance, the Loan Agreement balance will be reduced by $7 million [4] Leadership Changes - David Lazar was appointed as Chief Executive Officer and Principal Executive Officer by the Board, effective from the first closing of the financing [5] - Lazar previously served as CEO of Novabay Pharmaceuticals Inc. from August to November [5] Stock Performance - KALA BIO's stock has declined 91.72% year to date, with a 52-week range of $0.61 to $20.58 and a market capitalization of $5.21 million [6] - Benzinga's Edge Stock Rankings indicate a negative price trend for KALA stock across all time frames [6]